botulinum toxin A injection (AI-09) / Eirion - LARVOL DELTA

AI-09 In Subjects With Glabellar Lines, GL-101 (clinicaltrials.gov) - P1/2 | N=72 | Completed | Sponsor: Eirion Therapeutics Inc. | Active, not recruiting ➔ Completed

Trial completion

AI-09 In Subjects With Glabellar Lines, GL-101 (clinicaltrials.gov) - P1/2 | N=72 | Active, not recruiting | Sponsor: Eirion Therapeutics Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed

AI-09 In Subjects With Glabellar Lines, GL-101 (clinicaltrials.gov) - P1/2 | N=72 | Recruiting | Sponsor: Eirion Therapeutics Inc. | Trial completion date: Jan 2024 ➔ May 2024 | Trial primary completion date: Jan 2024 ➔ May 2024

Trial completion date • Trial primary completion date

AI-09 In Subjects With Glabellar Lines, GL-101 (clinicaltrials.gov) - P1/2 | N=72 | Recruiting | Sponsor: Eirion Therapeutics Inc. | Trial completion date: Sep 2023 ➔ Jan 2024 | Trial primary completion date: Sep 2023 ➔ Jan 2024

Trial completion date • Trial primary completion date